Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 21;7(1):46.
doi: 10.1038/s41537-021-00176-x.

No association between cortical dopamine D2 receptor availability and cognition in antipsychotic-naive first-episode psychosis

Affiliations

No association between cortical dopamine D2 receptor availability and cognition in antipsychotic-naive first-episode psychosis

Maria Lee et al. NPJ Schizophr. .

Abstract

Cognitive impairment is an important predictor of disability in schizophrenia. Dopamine neurotransmission in cortical brain regions has been suggested to be of importance for higher-order cognitive processes. The aim of this study was to examine the relationship between extrastriatal dopamine D2-R availability and cognitive function, using positron emission tomography and the high-affinity D2-R radioligand [11C]FLB 457, in an antipsychotic-naive sample of 18 first-episode psychosis patients and 16 control subjects. We observed no significant associations between D2-R binding in the dorsolateral prefrontal cortex or hippocampus (β = 0.013-0.074, partial r = -0.037-0.273, p = 0.131-0.841). Instead, using Bayesian statistics, we found moderate support for the null hypothesis of no relationship (BFH0:H1 = 3.3-8.2). Theoretically, our findings may suggest a lack of detrimental effects of D2-R antagonist drugs on cognition in schizophrenia patients, in line with clinical observations.

PubMed Disclaimer

Conflict of interest statement

S.C. has served as a one-off speaker for Otsuka Pharmaceuticals. L.F. was at the time of data collection partially employed at the AstraZeneca PET imaging Centre at Karolinska Institutet. C.M.S. is a scientific advisor to Outermost Therapeutics Inc. The remaining authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Relationship between [11C]FLB 457 BPND values and age-corrected cognitive test scores for the confirmatory analyses.
Blue circles indicate HC, red triangles indicate FEP. The gray area indicates a 95% confidence interval for the regression line. a BPND in DLPFC and verbal learning, b BPND in the hippocampus and verbal learning, c BPND in DLPFC and working memory, d BPND in DLPFC and speed of processing.

References

    1. Aas, M. et al. A systematic review of cognitive function in first-episode psychosis, including a discussion on childhood trauma, stress, and inflammation. Front. Psychiatry10.3389/fpsyt.2013.00182 (2014). - PMC - PubMed
    1. Bowie, C. R. & Harvey, P. D. Cognition in schizophrenia: impairments, determinants, and functional importance. Psychiatr. Clin. North Am.28, 613–33 (2005). - PubMed
    1. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12:426–445. doi: 10.1037/0894-4105.12.3.426. - DOI - PubMed
    1. Schaefer J, Giangrande E, Weinberger DR, Dickinson D. The global cognitive impairment in schizophrenia: consistent over decades and around the world. Schizophr. Res. 2013;150:42–50. doi: 10.1016/j.schres.2013.07.009. - DOI - PMC - PubMed
    1. Fatouros-Bergman, H., Cervenka, S., Flyckt, L., Edman, G. & Farde, L. Meta-analysis of cognitive performance in drug-naive patients with schizophrenia. Schizophr. Res. 158, 156–62 (2014). - PubMed